BeiGene - BGNE Stock Forecast, Price & News

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Wall Street Analyst Weigh In

Several brokerages recently commented on BGNE. StockNews.com upgraded shares of BeiGene from a "sell" rating to a "hold" rating in a report on Monday, August 8th. JPMorgan Chase & Co. restated an "overweight" rating and set a $296.00 price objective on shares of BeiGene in a report on Tuesday. Finally, Morgan Stanley dropped their price objective on shares of BeiGene from $300.00 to $293.00 and set an "overweight" rating on the stock in a report on Friday, July 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $299.25.

BeiGene Stock Performance

NASDAQ:BGNE opened at $193.97 on Friday. The stock has a market cap of $20.07 billion, a P/E ratio of -9.50 and a beta of 0.66. The company's 50-day simple moving average is $169.47 and its 200 day simple moving average is $176.95. BeiGene has a twelve month low of $118.18 and a twelve month high of $426.56. The company has a quick ratio of 4.87, a current ratio of 4.54 and a debt-to-equity ratio of 0.03.

Insider Activity at BeiGene

In other BeiGene news, CFO Julia Aijun Wang sold 295 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $158.50, for a total value of $46,757.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, insider Lai Wang sold 660 shares of the company's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $142.00, for a total transaction of $93,720.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Julia Aijun Wang sold 295 shares of the stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $158.50, for a total transaction of $46,757.50. The disclosure for this sale can be found here. Insiders have sold a total of 7,740 shares of company stock valued at $1,124,135 over the last quarter. 7.50% of the stock is owned by company insiders.